Antidiabetic medications

Article written and reviewed by Dr Luca Moretti

Antidiabetic medications include medicines with different mechanisms of action, used to correct hyperglycemia and reduce the risk of acute and chronic diabetes complications. The traditional term glucose-lowering medications does not fully describe their current role, because numerous classes exert favorable effects on body weight, cardiovascular risk, heart failure, and the progression of chronic kidney disease, partly independently of blood glucose reduction.

Treatment selection depends first of all on the type of diabetes. In type 1 diabetes mellitus, autoimmune destruction of pancreatic beta cells causes absolute insulin deficiency and makes continuous insulin administration essential. In type 2 diabetes mellitus, insulin resistance, progressive deterioration of beta-cell function, excessive hepatic glucose production, abnormal glucagon secretion, reduced incretin effect, increased renal glucose reabsorption, and adipose-tissue dysfunction coexist in varying proportions. Treatment must therefore be individualized according to the predominant metabolic defect, the severity of hyperglycemia, and the patient's clinical characteristics.

According to the eleventh edition of the IDF Diabetes Atlas, diabetes affected approximately 589 million adults aged 20 to 79 years in 2024, corresponding to 11.1% of the world's population in this age group. Unless the epidemiological trend is reversed, the number could reach approximately 853 million by 2050. Most cases are type 2 diabetes, often associated with overweight or obesity, arterial hypertension, dyslipidemia, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease.

The goal of modern pharmacologic therapy is therefore not merely to achieve an isolated glycated hemoglobin value, but to build a strategy capable of improving metabolic control without causing hypoglycemia, limiting weight gain, protecting target organs, and maintaining a good quality of life. Treatment must be integrated with appropriate medical nutrition therapy and physical activity, control of other cardiovascular risk factors, and a structured patient-education program.

Classification and mechanisms of action of antidiabetic medications

The classification of antidiabetic medications reflects the different pathophysiological processes on which they act. Some medicines directly replace missing insulin; others increase its secretion, improve its peripheral effectiveness, reduce hepatic glucose production, modulate the incretin system, slow intestinal carbohydrate absorption, or increase urinary glucose excretion.

Insulin is the only treatment capable of fully replacing an absolute insulin deficiency. Insulin binding to its tyrosine kinase receptor activates intracellular pathways including IRS, PI3K, and AKT, promoting translocation of GLUT4 transporters to the membrane of muscle and adipose cells. This increases peripheral glucose utilization, stimulates glycogen, lipid, and protein synthesis, and inhibits gluconeogenesis, glycogenolysis, lipolysis, and ketogenesis.

Insulin analogues are classified as prandial, basal, and premixed preparations according to their absorption rate and duration of action. Prandial formulations are used to control the rise in blood glucose associated with meals, whereas basal formulations counter hepatic glucose production between meals and overnight. Type 1 diabetes generally requires basal-prandial replacement through multiple injections or an insulin pump; in type 2 diabetes, insulin may be introduced as basal therapy and subsequently intensified according to the glycemic profile.

Metformin is a biguanide that primarily reduces excessive hepatic glucose production and, to a lesser extent, improves peripheral insulin sensitivity. Its effects depend on changes in the hepatocyte's energy and redox state, modulation of mitochondrial function, activation of pathways including AMPK, and interactions with the intestine, bile-acid metabolism, and microbiota. The relative contribution of the individual mechanisms in humans has not yet been definitively established.

Metformin does not directly stimulate insulin secretion and therefore has a very low intrinsic risk of hypoglycemia. It is generally weight-neutral or associated with modest weight loss, has well-established glycemic efficacy, and can be used as monotherapy or in combination with almost all other classes, provided kidney function and the clinical condition permit its use.

Sulfonylureas bind to the SUR1 component of ATP-sensitive potassium channels in pancreatic beta cells. Channel closure causes membrane depolarization, opening of voltage-dependent calcium channels, calcium influx, and release of insulin-containing granules. Because secretion may be stimulated even when blood glucose is not elevated, these medications can cause hypoglycemia.

Meglitinides also act on ATP-sensitive potassium channels, but have a faster onset and shorter duration than sulfonylureas. They are administered in relation to meals and act mainly on postprandial hyperglycemia. Their effect requires residual beta-cell function.

Thiazolidinediones, represented mainly by pioglitazone, are agonists of the nuclear receptor PPAR-gamma. The change in gene transcription induced by activation of this receptor promotes adipocyte differentiation, alters adipokine production, and improves the capacity of adipose tissue to store fatty acids, reducing their ectopic deposition in the liver and muscle.

The result is increased insulin sensitivity in adipose tissue, skeletal muscle, and the liver. The effect develops gradually over several weeks and does not depend on immediate stimulation of insulin secretion. Fluid and sodium retention, weight gain, and the risk of heart failure nevertheless limit its use in many patients.

Dipeptidyl peptidase 4 inhibitors prevent the rapid degradation of the endogenous incretin hormones GLP-1 and GIP. Their increased concentration promotes glucose-dependent insulin secretion and reduces inappropriate glucagon secretion. Glycemic efficacy is moderate, body weight generally remains stable, and hypoglycemia risk is low when they are not combined with insulin or secretagogues.

GLP-1 receptor agonists pharmacologically reproduce the action of glucagon-like peptide 1 with greater resistance to enzymatic degradation than the endogenous hormone. They increase insulin secretion and reduce glucagon secretion in a predominantly glucose-dependent manner, slow gastric emptying to a variable degree, and act on central circuits responsible for satiety and control of food intake.

The reduction in appetite and caloric intake enables weight loss that varies according to the agent and dose used. Certain GLP-1 receptor agonists have also demonstrated reductions in major cardiovascular events and, for specific agents and populations, clinically meaningful kidney benefits. These properties must not automatically be attributed to every member of the class to the same extent.

Dual incretin receptor agonists activate multiple receptors involved in metabolic regulation. Tirzepatide is a GIP and GLP-1 receptor agonist and integrates the effects of the two systems on insulin secretion, glucagon, satiety, and energy balance. In clinical trials it produced particularly marked reductions in glycated hemoglobin and body weight.

Sodium-glucose cotransporter 2 inhibitors block sodium and glucose reabsorption in the renal proximal tubule. The resulting glycosuria lowers blood glucose through a mechanism independent of insulin secretion and action and causes caloric loss associated with a modest reduction in body weight.

The increased sodium delivery to the macula densa restores tubuloglomerular feedback, reduces hyperfiltration and intraglomerular pressure, and contributes to kidney protection. Natriuresis, changes in renal hemodynamics, reduction in interstitial volume, and additional metabolic and energetic adaptations contribute to favorable effects on heart failure and progression of chronic kidney disease. These benefits may persist even when the glucose-lowering effect becomes less evident because of reduced kidney function.

Alpha-glucosidase inhibitors, such as acarbose, slow intestinal hydrolysis of complex carbohydrates and glucose absorption. They act mainly on the postprandial glycemic excursion without directly stimulating insulin secretion. The delivery of a larger amount of unabsorbed carbohydrate to the colon explains the frequent development of bloating and gastrointestinal disorders.

The different sites of action of the available classes make it possible to combine medicines with complementary mechanisms. The combination must nevertheless be rational: combining a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist with a DPP-4 inhibitor does not provide clinically significant additional benefit because both act on the same incretin system and is therefore not recommended.

Clinical indications and selection of pharmacologic therapy

Treatment selection requires correct classification of diabetes. A patient with autoimmune diabetes, advanced pancreatic disease, or another condition associated with severe insulin deficiency cannot be treated as an ordinary case of type 2 diabetes. In conditions characterized by absolute insulin deficiency, omission of insulin rapidly leads to severe hyperglycemia, uncontrolled lipolysis, ketogenesis, and diabetic ketoacidosis.

In type 1 diabetes, insulin must be started at diagnosis and continued without interruption. The regimen should reproduce physiological basal and prandial secretion as closely as possible and must be accompanied by education on carbohydrate counting, dose adjustment, hypoglycemia prevention, and management of physical activity and intercurrent illness. Automated insulin-delivery systems, when available and appropriate, improve time in the target glucose range and reduce the daily decision-making burden.

There is no single pharmacologic sequence appropriate for everyone with type 2 diabetes. The initial assessment must include the degree and course of hyperglycemia, presence of symptoms, unintentional weight loss, ketonemia or ketonuria, kidney function, albuminuria, atherosclerotic cardiovascular disease, heart failure, obesity, metabolic liver disease, hypoglycemia risk, frailty, life expectancy, preferences, self-management capacity, cost, and medication access.

Glycated hemoglobin provides an estimate of average glycemic exposure but does not fully describe postprandial excursions, variability, or hypoglycemic episodes. Treatment decisions must therefore integrate glycated hemoglobin, capillary glucose values or continuous monitoring, weight trends, symptoms, and the overall clinical condition.

In the presence of polyuria, polydipsia, dehydration, weight loss, ketosis, or other signs of catabolism, insulin is often the most rapid and reliable initial treatment. Guidelines also recommend considering it when glycated hemoglobin exceeds 10% or blood glucose reaches or exceeds approximately 300 mg/dL, especially when the condition is symptomatic or substantial insulin deficiency cannot be excluded.

Initial insulin therapy is not necessarily permanent in type 2 diabetes. After resolution of glucotoxicity and partial recovery of beta-cell function, it may be possible to reduce the dose or replace part of insulin therapy with noninsulin medications, provided the patient is reassessed and remains under metabolic control.

When severe hyperglycemia is absent and injectable therapy is required, recent recommendations generally favor a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist before insulin. These medications combine high glycemic efficacy with weight loss and a low intrinsic risk of hypoglycemia. Insulin remains essential, however, when substantial insulin deficiency is present, when incretin-based therapies are contraindicated or not tolerated, or when the response is insufficient.

Metformin remains a common initial option in patients without predominant indications for other classes because of its efficacy, long clinical experience, low risk of hypoglycemia, and low cost. It should not, however, be regarded as the mandatory first and only treatment before medications with documented cardiovascular or kidney benefits may be prescribed.

In patients with established atherosclerotic cardiovascular disease or particularly high cardiovascular risk, preference should be given to GLP-1 receptor agonists and SGLT2 inhibitors that have demonstrated reductions in cardiovascular events in their respective trials. Selection depends on the predominant clinical profile, kidney function, and the specific evidence available for each agent, as discussed in the page on antidiabetic medications and cardiovascular risk.

In patients with heart failure, regardless of ejection fraction, SGLT2 inhibitors have a priority role because they reduce the risk of hospitalization for heart failure and improve cardiovascular outcomes. The effect should not be interpreted as exclusively resulting from glucose reduction and has also been observed in people without diabetes.

In type 2 diabetes associated with chronic kidney disease, an SGLT2 inhibitor with demonstrated kidney efficacy is recommended when the glomerular filtration rate and approved indications permit initiation. KDIGO guidelines generally indicate an estimated glomerular filtration rate threshold of at least 20 mL/min/1.73 m², while the conditions specified for the particular agent must still be observed.

At low glomerular filtration rates, the glycemic effect of SGLT2 inhibitors decreases, whereas cardiorenal protection may remain clinically important. If metabolic control remains inadequate, the SGLT2 inhibitor is not tolerated, or additional organ protection is needed, a GLP-1 receptor agonist with documented cardiovascular and kidney benefits may be introduced. Management is discussed in greater detail on the page about antidiabetic medications in chronic kidney disease.

Metformin can generally be used when the estimated glomerular filtration rate is at least 30 mL/min/1.73 m². Below 45 mL/min/1.73 m², the dose, kidney-function trend, and conditions that may lead to medication accumulation must be reassessed; below 30 mL/min/1.73 m², treatment is contraindicated.

In patients with overweight or obesity, medication selection must consider the effect on weight as an integral component of diabetes treatment. GLP-1 receptor agonists and tirzepatide have the greatest average weight-loss efficacy among commonly used noninsulin antidiabetic medications. SGLT2 inhibitors produce a more modest reduction, whereas metformin, DPP-4 inhibitors, and acarbose are generally weight-neutral or nearly neutral.

Insulin, sulfonylureas, meglitinides, and pioglitazone can promote weight gain through different mechanisms. Selection must therefore balance the metabolic benefit against the potential effect on weight, as described on the page about antidiabetic medications and obesity.

When hypoglycemia risk is high, as in frail older adults and people with kidney disease, cognitive impairment, irregular meals, or previous severe episodes, classes with a low intrinsic risk should be preferred. Metformin, DPP-4 inhibitors, GLP-1 receptor agonists, tirzepatide, SGLT2 inhibitors, pioglitazone, and acarbose do not usually cause hypoglycemia as monotherapy, whereas insulin, sulfonylureas, and meglitinides require greater caution.

Frailty, multimorbidity, or limited life expectancy may make less stringent glycemic targets and simpler treatment regimens appropriate. In these circumstances, deintensification of insulin or secretagogues may be safer than adding further medications to achieve an excessively low glycemic value.

Pioglitazone may be useful when insulin resistance is marked and in some patients with metabolic steatohepatitis, provided current or prior heart failure, hepatic impairment, diabetic ketoacidosis, current or prior bladder cancer, unexplained macroscopic hematuria, and other contraindications are absent. GLP-1 receptor agonists and tirzepatide may improve weight, metabolic parameters, and some manifestations of metabolic liver disease, but prescribing must comply with approved indications and the overall hepatologic condition.

DPP-4 inhibitors are used primarily when a well-tolerated oral treatment that is weight-neutral and has a low risk of hypoglycemia is required. Their glycemic efficacy is generally lower than that of GLP-1 receptor agonists, and they do not have the same effects on weight. Most require dose adjustment in kidney disease, with differences among individual agents.

Sulfonylureas and meglitinides can lower blood glucose rapidly and retain a role in patients for whom cost, availability, or contraindications limit the use of other classes. They must nevertheless be prescribed with consideration of duration of action, kidney function, meal regularity, and hypoglycemia risk.

When baseline glycated hemoglobin exceeds the individualized target by approximately 1.5-2 percentage points, initial combination therapy may achieve control more rapidly and reduce the risk of therapeutic inertia. Early combination is also appropriate when one class is indicated for cardiovascular or kidney protection independently of the glycated hemoglobin value.

The choice of medication in type 2 diabetes must therefore be reassessed over time. Progression of beta-cell dysfunction, development of new comorbidities, a change in kidney function, weight loss or gain, and changes in social circumstances may alter the benefit-risk balance of a previously appropriate therapy.

During pregnancy, insulin is the pharmacologic treatment of choice because of its efficacy and inability to cross the placenta. Use of other medicines must be decided by specialists according to the type of diabetes, available evidence, and regulatory indications. Similar caution is required during breastfeeding and in pediatric patients.

Prescribing, titration, and treatment monitoring

Prescription of an antidiabetic medication must be preceded by definition of an individualized therapeutic target. For many nonpregnant adults, glycated hemoglobin below 7% is a reasonable reference, but the target may be more stringent in young patients at low risk of hypoglycemia or less stringent in the presence of frailty, advanced comorbidities, recurrent hypoglycemic episodes, or limited life expectancy.

The treatment plan must specify the expected result, timing of reassessment, and criteria for increasing, reducing, replacing, or discontinuing the medication. A prescription without a monitoring plan promotes both therapeutic inertia, when ineffective treatment is maintained too long, and overtreatment, when potentially dangerous medicines are not reduced despite metabolic improvement.

Glycated hemoglobin is generally reassessed about three months after treatment initiation or modification because this interval allows its effect on erythrocyte glycation to be evaluated. Testing may be less frequent in patients with stable control but should be brought forward in the presence of symptoms, hypoglycemia, rapid metabolic deterioration, pregnancy, or significant clinical changes.

Capillary glucose monitoring is particularly important in patients treated with insulin, sulfonylureas, or meglitinides and during titration. Continuous glucose monitoring makes it possible to assess time in range, hypoglycemia, variability, and postprandial excursions and may provide information unavailable from glycated hemoglobin alone.

Before metformin or SGLT2 inhibitors are started, an estimate of kidney function and an assessment of conditions that may promote dehydration or acute kidney injury must be available. Kidney function must be rechecked periodically, with increasing frequency as filtration declines or acute illnesses occur.

Metformin should be introduced gradually and taken according to the prescribed formulation because progressive titration reduces nausea, abdominal pain, and diarrhea. During prolonged treatment, vitamin B12 measurement should be considered, particularly in the presence of anemia, neuropathy, an inadequate diet, or other predisposing factors.

In cases of vomiting, significant diarrhea, dehydration, sepsis, hypoxia, acute kidney injury, or another condition that may promote metformin accumulation, treatment must be temporarily reassessed. Discontinuation around administration of iodinated contrast medium depends on kidney function, the route of administration, and acute kidney injury risk and must follow applicable clinical procedures.

SGLT2 inhibitors require appropriate education about the possible development of polyuria, genital fungal infections, and symptoms of volume depletion. A modest reversible reduction in glomerular filtration rate may occur after initiation because of correction of hyperfiltration; this hemodynamic phenomenon does not necessarily indicate kidney injury and must be interpreted in the clinical context.

The development of nausea, vomiting, abdominal pain, abnormal breathing, or marked fatigue in a patient taking an SGLT2 inhibitor should raise consideration of ketoacidosis even when blood glucose is not markedly elevated. The medication should be temporarily discontinued during prolonged fasting, severe acute illness, and conditions characterized by reduced food intake or increased insulin requirements.

Before planned surgery, SGLT2 inhibitors must be stopped sufficiently in advance to reduce the risk of perioperative ketoacidosis. Recommendations generally indicate at least three days for most agents and four days for ertugliflozin, unless different clinical or regulatory instructions apply.

GLP-1 receptor agonists and tirzepatide should be titrated gradually. Increasing the dose too rapidly worsens nausea, fullness, vomiting, diarrhea, or constipation and may lead to discontinuations that could have been avoided with slower titration. Weight trend, digestive tolerability, hydration, and adequacy of nutritional intake must be assessed during treatment.

In people with symptoms of gastroparesis or another severe gastrointestinal motility disorder, use of incretin-based medicines requires particular caution. Severe and persistent abdominal pain, especially when radiating to the back and associated with vomiting, requires urgent assessment to exclude pancreatitis or biliary disease.

When a GLP-1 receptor agonist or tirzepatide is added to insulin or a sulfonylurea, it may be necessary to reduce the dose of the medication responsible for hypoglycemia in advance. The same principle applies when a significant improvement in weight and insulin resistance progressively reduces insulin requirements.

Sulfonylureas and meglitinides must be coordinated with meal intake. The patient must receive instructions on recognition and treatment of hypoglycemia, management of skipped meals, physical activity, and alcohol consumption. Reduced kidney function may prolong the effect of certain agents and make hypoglycemic episodes more persistent.

During pioglitazone treatment, weight, dependent edema, dyspnea, and other signs of fluid retention or heart failure must be monitored. Rapid weight gain should not automatically be attributed to increased fat mass because it may reflect fluid accumulation.

DPP-4 inhibitors generally require few clinical adjustments, but the dosage of several agents must be adapted to the glomerular filtration rate. Development of severe joint pain, blistering skin lesions, or suspected pancreatitis requires reassessment of treatment.

Acarbose is introduced at gradually increasing doses and taken at the beginning of the meal. If the patient is also receiving insulin or a secretagogue and develops hypoglycemia, it must be treated with directly absorbable glucose because the medication slows digestion of sucrose and complex carbohydrates.

Insulin therapy requires practical training in injection technique, site rotation, device storage, dose correction, and hypoglycemia treatment. Repeated injection into the same area promotes lipohypertrophy, makes absorption unpredictable, and can cause alternating hyperglycemia and hypoglycemia.

Insulin requirements vary with diet, physical activity, stress, infections, corticosteroid therapy, kidney function, and weight changes. In type 1 diabetes, basal insulin must not be stopped during intercurrent illness or in the absence of food intake because insulin deficiency would rapidly promote ketogenesis.

A person treated with insulin must know sick-day rules, ketone testing, correction of hyperglycemia, and the criteria for seeking urgent care. Glucagon should be available for patients at risk of severe hypoglycemia, and family members or caregivers must be trained in its use.

At every visit, adherence, administration difficulties, cost, medication availability, understanding of the regimen, and adverse effects must be assessed. Apparent pharmacologic inefficacy may result from missed doses, incorrect injection technique, inability to afford the medication, or excessive regimen complexity.

Polypharmacy should be periodically simplified by eliminating unhelpful combinations, duplication of mechanisms, and medicines whose risk has become greater than their benefit. Dose reduction or discontinuation may be indicated after substantial weight loss, metabolic surgery, worsening kidney function, development of frailty, or recurrent hypoglycemic episodes.

Discontinuation must nevertheless also consider extraglycemic effects. A patient with controlled glycated hemoglobin may continue to have an indication for an SGLT2 inhibitor or a specific GLP-1 receptor agonist for cardiovascular or kidney protection. Lack of a glucose-lowering need does not necessarily mean lack of clinical benefit.

Clinical efficacy, target-organ protection, and prognosis

The efficacy of an antidiabetic medication cannot be judged solely by the average reduction in glycated hemoglobin. The speed and duration of response, effects on fasting and postprandial glucose, hypoglycemia risk, weight change, tolerability, cardiovascular and kidney protection, treatment simplicity, and the patient's ability to sustain treatment over the long term must all be considered.

In general terms, adding a common oral class can reduce glycated hemoglobin by approximately 0.7-1 percentage point, but individual response varies widely according to the baseline value, diabetes duration, beta-cell function, kidney function, and adherence. Insulin, semaglutide, and tirzepatide are among the options with the greatest average glycemic potency.

Insulin has no theoretical maximum glucose-lowering efficacy because the dose can be adapted to requirements. This potency is counterbalanced by hypoglycemia risk, weight gain, and the need for more complex management. Continuously increasing the dose without assessing diet, injection technique, physical activity, and insulin resistance may produce a burdensome and poorly effective regimen.

The DCCT in type 1 diabetes and UKPDS in type 2 diabetes demonstrated that improved glycemic control primarily reduces the incidence and progression of microvascular complications, including retinopathy, kidney disease, and neuropathy. The benefit may persist over time through the so-called metabolic memory effect, making it particularly important to avoid prolonged exposure to hyperglycemia in the early stages of the disease.

Intensive glucose lowering does not, however, produce the same results at every stage of diabetes. In older or frail patients and those with advanced cardiovascular disease, excessively aggressive targets achieved with medications that cause hypoglycemia may increase adverse events without providing proportionate benefit. Prognosis improves when treatment intensity and tools are consistent with the individual profile.

The comparative GRADE study showed that, in patients with type 2 diabetes treated with metformin, insulin glargine and liraglutide maintained glycemic control slightly longer than glimepiride and sitagliptin. None of the strategies completely prevented progressive loss of control, confirming the evolving nature of beta-cell dysfunction.

Metformin has well-established efficacy and extensive clinical experience. Historical UKPDS data suggested clinical benefits in patients with overweight, but contemporary selection should not be based on automatically attributing to metformin the same cardiovascular benefits documented in dedicated trials for specific SGLT2 inhibitors and GLP-1 receptor agonists.

Sulfonylureas reduce blood glucose rapidly and are economically accessible, but their effect tends to diminish with progressive loss of beta-cell function. Hypoglycemia risk and weight gain affect their prognosis particularly in older patients, those with kidney disease, and those with a reduced ability to recognize symptoms.

DPP-4 inhibitors provide moderate glycemic control and good tolerability, with weight neutrality and a low intrinsic risk of hypoglycemia. The main cardiovascular trials have generally demonstrated safety regarding atherosclerotic events but not a consistent reduction in major cardiovascular events. An increase in hospitalizations for heart failure was also observed with saxagliptin.

Pioglitazone can produce a relatively durable improvement in insulin sensitivity, and some data suggest favorable effects on specific vascular outcomes and metabolic steatohepatitis. Its clinical usefulness must nevertheless be balanced against fluid retention, weight gain, heart failure, and fracture risk.

GLP-1 receptor agonists differ in structure, duration of action, metabolic efficacy, and evidence regarding clinical outcomes. Liraglutide, semaglutide, and dulaglutide have demonstrated reductions in major cardiovascular events in different populations. Results obtained with a specific agent should not automatically be extended to all others.

In the FLOW study, semaglutide also demonstrated reductions in clinically important kidney outcomes and cardiovascular mortality in patients with type 2 diabetes and chronic kidney disease. This result strengthens the role of incretin-based therapies in organ protection without replacing the complementary role of SGLT2 inhibitors.

Tirzepatide produces reductions in glycated hemoglobin and body weight greater than those observed with several comparators in metabolic trials. In SURPASS-CVOT, it was noninferior to dulaglutide for the composite of cardiovascular death, myocardial infarction, and stroke in patients with type 2 diabetes and atherosclerotic disease, without demonstrating statistical superiority for the primary endpoint.

Weight loss achieved with GLP-1 receptor agonists and tirzepatide may improve blood pressure, lipid profile, mobility, obstructive sleep apnea, and parameters of metabolic liver disease. These effects contribute to the overall benefit but must be maintained through treatment continuity and lifestyle interventions because discontinuation may be followed by weight regain.

SGLT2 inhibitors have profoundly changed management of cardiorenal risk. EMPA-REG OUTCOME documented reductions in cardiovascular mortality and hospitalizations for heart failure with empagliflozin in patients with type 2 diabetes and cardiovascular disease. Subsequent studies confirmed benefits on heart failure and progression of kidney disease in broader populations.

DAPA-CKD and EMPA-KIDNEY demonstrated that dapagliflozin and empagliflozin reduce progression of kidney disease and cardiorenal outcomes in patients with chronic kidney disease, including those without diabetes. This confirms that the kidney protection provided by SGLT2 inhibitors is not simply a consequence of glycosuria or glycated hemoglobin reduction.

Combining medications with complementary mechanisms makes it possible to act simultaneously on multiple components of pathophysiology. In selected patients, metformin, an SGLT2 inhibitor, and a GLP-1 receptor agonist can provide integrated effects on glycemia, weight, and cardiorenal risk with a low intrinsic risk of hypoglycemia.

When insulin is added, continuing metformin and medications with cardiorenal benefit may reduce insulin requirements and preserve organ protection, provided no contraindications exist. Combining insulin with a GLP-1 receptor agonist or tirzepatide may improve glycemic control while limiting weight gain and hypoglycemia compared with insulin intensification alone.

The prognosis of diabetes also depends on control of blood pressure, LDL cholesterol, smoking, diet, physical activity, and obesity. An antidiabetic medication does not replace statins, antihypertensive therapy, kidney protection, antithrombotic treatment when indicated, or systematic screening for complications.

Substantial weight loss, whether spontaneous or achieved through intensive treatment or metabolic surgery, can lead to remission of type 2 diabetes in some patients. Remission is not equivalent to a definitive cure: the risk of recurrent hyperglycemia persists, and metabolic monitoring and surveillance of previous complications must continue.

Early, individualized treatment therefore improves prognosis through three complementary pathways: reducing chronic exposure to hyperglycemia, preventing hypoglycemia, and selectively using medicines capable of directly modifying cardiovascular or kidney risk. The best medication is not necessarily the one that produces the greatest glucose reduction, but the one that offers the most favorable balance of efficacy, safety, organ protection, and sustainability for the individual patient.

Adverse effects, contraindications, and treatment complications

Hypoglycemia is the most important pharmacologic complication of treatment with insulin, sulfonylureas, and meglitinides. It results from a relative excess of insulin in relation to the amount of available glucose and may be promoted by an excessive dose, a skipped meal, unplanned physical activity, alcohol consumption, weight loss, kidney or liver impairment, and administration errors.

Autonomic symptoms include tremor, sweating, palpitations, hunger, and anxiety, whereas neuroglycopenia may cause confusion, visual disturbances, behavioral changes, seizures, loss of consciousness, and coma. Repeated episodes may blunt warning signals and lead to impaired awareness of hypoglycemia, increasing the risk of severe events.

Hypoglycemia can cause falls, trauma, motor-vehicle accidents, arrhythmias, and deterioration in quality of life. Prevention requires education, dose review, glucose monitoring, and, when necessary, replacement or deintensification of the responsible medicines.

Insulin can cause weight gain because it reduces urinary glucose loss, inhibits catabolism, and facilitates nutrient storage. Other effects include lipohypertrophy at injection sites, transient edema, local reactions, and, very rarely, allergy. Errors involving different concentrations or devices may cause potentially severe overdoses.

Metformin frequently causes nausea, diarrhea, abdominal pain, and taste disturbances, particularly during the initial phases. Gradual titration and use of extended-release formulations may improve tolerability. Prolonged treatment may reduce vitamin B12 absorption and contribute to anemia or neuropathy.

Metformin-associated lactic acidosis is rare but may occur when a substantial reduction in renal elimination is combined with hypoxia, shock, sepsis, advanced liver failure, or another condition capable of increasing lactate production or reducing its clearance. The medication must not be used with an estimated glomerular filtration rate below 30 mL/min/1.73 m².

Sulfonylureas and meglitinides can cause hypoglycemia and weight gain. Episodes induced by long-acting sulfonylureas may persist or recur, particularly in older people and those with kidney disease. Prescribing must take account of pharmacokinetic differences among individual agents.

Pioglitazone promotes sodium and water retention, peripheral edema, and weight gain. Expansion of plasma volume may precipitate or worsen heart failure and makes the medication contraindicated in patients with current or prior heart failure, NYHA class I to IV, according to the European summary of product characteristics.

Thiazolidinediones also increase fracture risk, particularly in women, and may be associated with macular edema. For pioglitazone, the European summary of product characteristics contraindicates use in patients with current or prior bladder cancer, unexplained macroscopic hematuria, hepatic impairment, and diabetic ketoacidosis.

DPP-4 inhibitors are generally well tolerated, but acute pancreatitis, severe joint pain, and bullous pemphigoid have been reported. Some agents require dose reduction in kidney disease. Saxagliptin should be used with particular caution in patients at risk of heart failure because of the signal observed in cardiovascular trials.

GLP-1 receptor agonists and tirzepatide primarily cause nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. These disorders are generally more pronounced during dose escalation and may cause dehydration, worsening kidney function, or excessive loss of lean mass in vulnerable patients.

Reduced gastrointestinal motility may worsen pre-existing gastroparesis. Cholelithiasis, cholecystitis, and, less commonly, pancreatitis are also possible. A previous episode of pancreatitis or biliary disease requires an individualized assessment of benefits and risks.

Rapid improvement in glycemia may be followed by transient worsening of diabetic retinopathy, a phenomenon already known with intensive insulin therapy and also observed in some studies of potent incretin-based therapies. Patients with advanced retinopathy require ophthalmologic monitoring and carefully planned glucose reduction.

The specific contraindications of incretin receptor agonists differ among agents and formulations. Prescribing must review the endocrine history, gastrointestinal disease, pregnancy, kidney function, and indications in the summary of product characteristics, avoiding automatic attribution of the same limitations to the entire class.

SGLT2 inhibitors increase urinary glucose concentration and promote vulvovaginal candidiasis and balanitis. Infections are generally treatable but may recur. Appropriate hygiene, early symptom recognition, and management of predisposing factors reduce their impact.

Natriuresis and osmotic diuresis can cause polyuria, hypotension, and volume depletion, especially in older people, patients treated with diuretics, or those with reduced fluid intake. Blood pressure, hydration status, and concomitant therapy must be assessed before treatment begins.

Ketoacidosis associated with SGLT2 inhibitors may present with lower blood glucose values than conventional diabetic ketoacidosis. Fasting, surgery, infections, excessive insulin reduction, high alcohol consumption, a very-low-carbohydrate diet, and unrecognized insulin deficiency increase risk.

Fournier gangrene is an extremely rare but serious complication reported during treatment with SGLT2 inhibitors. Pain, swelling, erythema, or fever involving the perineal region requires urgent assessment. An increase in amputations was observed with canagliflozin in one study but was not consistently confirmed in subsequent studies; careful surveillance is nevertheless required in patients with foot lesions or severe peripheral arterial disease.

Acarbose frequently causes flatulence, bloating, abdominal pain, and diarrhea because of colonic fermentation of unabsorbed carbohydrates. It is contraindicated or inappropriate in major inflammatory bowel diseases, conditions associated with obstruction or clinically significant malabsorption, and some forms of advanced liver or kidney failure.

Combining several medicines may add their adverse effects. Insulin combined with a sulfonylurea increases hypoglycemia risk; pioglitazone combined with insulin accentuates edema and weight gain; diuretics and SGLT2 inhibitors may increase volume depletion; and medicines that slow gastrointestinal motility may worsen the tolerability of incretin-based therapies.

Polypharmacy may also produce errors, poor adherence, and duplication. A pharmacologically correct regimen that is too complex for the patient's cognitive, visual, manual, or social abilities becomes clinically unsafe. The number of administrations, devices, and instructions must be compatible with daily life and the possible availability of caregivers.

The side effects and contraindications of antidiabetic medications must be reassessed whenever kidney function, weight, diet, cognitive status, comorbidities, or concomitant therapy change. A previously safe class may become inappropriate as age or disease advances.

Development of an adverse effect does not necessarily require abandonment of the entire pharmacologic strategy. Dose reduction, slower titration, correction of predisposing factors, replacement with an agent in the same class that has different characteristics, or transition to another mechanism may preserve benefits while reducing risk.

Treatment must be urgently reassessed in the presence of severe hypoglycemia, ketosis, acidosis, substantial dehydration, rapid deterioration of kidney function, suspected pancreatitis, heart failure, an allergic reaction, or inability to eat. Prevention of pharmacologic complications depends primarily on patient education, individualized prescribing, and periodic review of the benefit-risk balance.

References
1. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes, 2026. Diabetes Care. 2026;49(Suppl 1):S183-S215.
2. Davies MJ et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 45(11), 2022, 2753-2786.
3. Holt RIG et al. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 44(11), 2021, 2589-2625.
4. Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 102(5S), 2022, S1-S127.
5. de Boer IH et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association and Kidney Disease: Improving Global Outcomes. Diabetes Care. 45(12), 2022, 3075-3090.
6. Marx N et al. 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. European Heart Journal. 44(39), 2023, 4043-4140.
7. Genitsaridi I et al. 11th Edition of the IDF Diabetes Atlas: Global, Regional, and National Diabetes Prevalence Estimates for 2024 and Projections for 2050. The Lancet Diabetes & Endocrinology. 14(2), 2026, 149-156.
8. DeFronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes. 58(4), 2009, 773-795.
9. Rena G et al. The Mechanisms of Action of Metformin. Diabetologia. 60(9), 2017, 1577-1585.
10. Soccio RE et al. Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes. Cell Metabolism. 20(4), 2014, 573-591.
11. Thomas MC et al. The Actions of SGLT2 Inhibitors on Metabolism, Renal Function and Blood Pressure. Diabetologia. 61(10), 2018, 2098-2107.
12. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 46, 2021, 101102.
13. Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 329(14), 1993, 977-986.
14. UK Prospective Diabetes Study Group. Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes. The Lancet. 352(9131), 1998, 837-853.
15. UK Prospective Diabetes Study Group. Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes. The Lancet. 352(9131), 1998, 854-865.
16. Nathan DM et al. Glycemia Reduction in Type 2 Diabetes: Glycemic Outcomes. New England Journal of Medicine. 387(12), 2022, 1063-1074.
17. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 373(22), 2015, 2117-2128.
18. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 375(4), 2016, 311-322.
19. Gerstein HC et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes: A Double-Blind, Randomised Placebo-Controlled Trial. The Lancet. 394(10193), 2019, 121-130.
20. Scirica BM et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine. 369(14), 2013, 1317-1326.
21. Dormandy JA et al. Secondary Prevention of Macrovascular Events in Patients with Type 2 Diabetes in the PROactive Study: A Randomised Controlled Trial. The Lancet. 366(9493), 2005, 1279-1289.
22. Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 383(15), 2020, 1436-1446.
23. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 388(2), 2023, 117-127.
24. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 391(2), 2024, 109-121.
25. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 385(6), 2021, 503-515.
26. Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine. 393(24), 2025, 2409-2420.
27. Umpierrez GE et al. Hyperglycemic Crises in Adults with Diabetes: A Consensus Report. Diabetes Care. 47(8), 2024, 1257-1275.